Want to join the conversation?
$VRX said it received a unanimous FDA Advisory Committee vote for Brodalumab on July 19, 2016. The panel voted 18-0 in favor of this approval. Brodalumab showed statistical superiority versus Stelara, which has worldwide sales of over $2.7Bil in 2015. The drug also demonstrated impressive clearance rates and has a rapid onset of action.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.